Active Ingredient History
Ixazomib (MLN2238) is an active metabolite of orally bioavailable proteasome inhibitor ixazomib citrate (MLN9708), which hydrolyzes upon administration. Ixazomib citrate was approved under the name Ninlaro for the treatment of multiple myeloma in patients who have received at least one prior therapy. In vitro studies has shown that ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Amyloidosis (Phase 3)
Anemia, Hemolytic, Autoimmune (Phase 2)
Biomarkers (Phase 2)
Breast Neoplasms (Phase 1)
Burkitt Lymphoma (Phase 1/Phase 2)
Carcinoma (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 1/Phase 2)
Chromosome Aberrations (Phase 1/Phase 2)
Genetic Diseases, Inborn (Phase 2)
Glioblastoma (Phase 1)
Graft vs Host Disease (Phase 2)
Hematologic Neoplasms (Phase 1)
Hematopoietic Stem Cell Transplantation (Phase 3)
HIV Infections (Phase 1/Phase 2)
Immunoglobulin Light-chain Amyloidosis (Phase 2)
Kidney Diseases (Phase 2)
Kidney Failure, Chronic (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 1)
Leukemia, Monocytic, Acute (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myelomonocytic, Acute (Phase 2)
Leukemia, Plasma Cell (Phase 2)
Liposarcoma (Phase 1)
Lung Diseases (Phase 2)
Lung Diseases, Interstitial (Phase 2)
Lupus Nephritis (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 1/Phase 2)
Multiple Sclerosis, Chronic Progressive (Phase 1)
Multiple Sclerosis, Relapsing-Remitting (Phase 1)
Mutation (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoplasms ()
Neurofibrosarcoma (Phase 1)
Plasmablastic Lymphoma (Phase 1/Phase 2)
Plasmacytoma (Phase 3)
POEMS Syndrome (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 2)
Sarcoma (Phase 1)
Sarcoma, Alveolar Soft Part (Phase 1)
Sarcoma, Ewing (Phase 1)
Sarcoma, Kaposi (Phase 2)
Scleroderma, Diffuse (Phase 2)
Scleroderma, Systemic (Phase 2)
Sclerosis (Phase 2)
Skin (Phase 2)
Smoldering Multiple Myeloma (Phase 2)
Translocation, Genetic (Phase 1/Phase 2)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
